Most of the studies have focused on the association between clinical factors in NSCLC patients with EGFR mutations and the survival time (20, 21, 26) while few studies have assessed the correlation between Ki-67 and first-line therapeutic outcomes in NSCLC patients with EGFR-mutant status. This evidence concerns the gene MKI67 and non-small cell lung carcinoma.